Issue link: https://viewer.e-digitaledition.com/i/237564
Cardiology Technology Advancements PRODUCT SPOTLIGHT By Joe Dodd IMAGE COURTESY OF KEYSTONE HEART TriGuard Developed by Keystone Heart, TriGuard is designed to provide protection to the aortic cerebral branches and reduce the risk of brain damage. By using a Nitinol frame and mesh, the device offers protection to the aortic arch and from any procedure-related tools and accessories. This technology is flexible yet provides sturdy protection to the aortic arch during procedures. TriGuard is inserted in the femoral artery access ports and will self-position via a 9F catheter. Keystone Heart, located in Israel, recently received CE marking for TriGuard, making it commercially available in the European Economic Area (EEA). The device is not yet available in the United States or outside the EEA. To learn more about TriGuard and other Keystone Heart products, visit www.keystoneheart.com. I Nit-Occlud PDA The Nit-Occlud PDA system is used for the safe, long-term treatment of the congenital heart defect known as persistent ductus arteriosus (PDA). A spiral coil made of nitinol is inserted on the pulmonary artery side via a 4-5F implantation catheter. The coil is fed out of the catheter to achieve occlusion of the PDA, and can be repositioned prior to release to ensure proper fit. Nit-Occlud PDA provides long-term treatment of PDA. PFM Medical, located in Germany, developed the Nit-Occlud PDA. The company recently received premarket approval from the FDA for commercial sales within the United States. Nit-Occlud PDA is currently available outside of the United States. More information about Nit-Occlud PDA and PFM Medical can be accessed at www.pfmmedical.com. I therapy devices. With this approval, BIOTRONIK has announced the launch of Ilesto DX. The new DX line is 15 percent smaller and uses 29 percent fewer components, making it a less invasive, long-term solution for patients requiring an ICD. The Ilesto DX provides greater capability and stability in the pursuit of quality outcomes for patients. Many healthcare professionals are expected to adopt the new system, based on BIOTRONIK's past success with the Ilesto line. The system is the first to use a single, specialized defibrillator lead while providing full atrial diagnostic information for healthcare professionals and their patients. Ilesto DX is currently limited in the United States to investigational use. To learn more about BIOTRONIK, visit www.biotronik.com. I IMAGE COURTESY OF PFM MEDICAL Ilesto DX BIOTRONIK, located in Germany, recently received FDA approval for its Ilesto line of implantable cardioverterdefibrillator (ICD) and resynchronization IMAGE COURTESY OF BIOTRONIK MDNEWS.COM ■ MD NEWS San Antonio |9